UK: Actavis v Eli Lilly

Last Updated: 23 November 2017
Article by Gwilym Roberts

What patent attorneys and examiners need to know about the UK's, and perhaps Europe's, biggest infringement case for 12 years.

 With the recent decision in Actavis v Eli Lilly Lord Neuberger has rethought, and rewritten, the rules of infringement. After 35 years of doctrinal development going back to the legendary Catnic case and seemingly settled in Kirin-Amgen in 2005, the Supreme Court has injected a nitro boost and taken the lead in establishing a test applicable across Europe. Litigators are going wild for it, but it is vital to look at the challenge that has been laid down to the patent makers, getters and even granters as it could have major ramifications for the day job.

The basics of the case

Eli Lilly were working on Pemetrexed, which is conventionally used to treat tumours in its free acid form - which is toxic. After a very broad initial claim to use of a methylmalonic acid, and the usual added matter wranglings at the EPO, claims were granted to Eli Lilly directed to a specific salt, Pemetrexed disodium - which is less toxic. Actavis used different Pemetrexed salts with the same effect. "A fight ensued, which presumably wouldn't have happened if an amendment had been available to 'a Pemetrexed salt' and it went all the way to the Supreme Court."

The decision

It looks like Lord Neuberger felt that there was infringement, and that infringement would be found in other European jurisdictions. But, application of the UK's current 'Protocol questions' (Reminder: is there an immaterial variant? Would that have been obvious at the publication date? Was strict compliance intended nonetheless?) would not deliver that result.

The old test

The Catnic-to-Kirin-Amgen suite of cases tells us that you shouldn't do the following: 1) look for literal infringement; 2) if that doesn't catch the infringement, apply the Protocol questions. Instead, there is supposed to be a 'single cause of action'. You just interpret the claim and work out what it is intended to mean, kind of in vacuo and without knowledge of the infringement's effects. That approach has been criticised in the past and probably isn't what anyone does, though they will pay lip service to it.

The new test

Here, Lord Neuberger has effectively said 'what about the Protocol to Art.69 EPC - which the Protocol questions are supposed to reflect? It is directed to determining the extent of protection, not to interpreting a claim, and it mentions equivalents!' He holds that shoehorning the equivalents issue via the 'immaterial variants' aspect into a single interpretation step can lead to errors. Instead, we should now interpret and if that doesn't settle it, apply a more equivalents-driven variant of the Protocol questions (step two above) to determine the extent of protection. We're also allowed knowledge of the result achieved by the variant.

The new test in this case – equivalents

The facts in this case give a good illustration and, given that the revised approach reflects what many practitioners were probably inadvertently doing anyway, is unlikely to be dismissed as being fact or technology specific.

First, the interpretation step. The Actavis product did not use Pemetrexed disodium, but neat Pemetrexed or different salts thereof. These do not infringe on a normal interpretation of the claim.

Second, the three revised Protocol questions. The first reformulated question is relatively unchanged and could be paraphrased as 'is it an equivalent?' The judge held that the Actavis products achieved substantially the same result in substantially the same way - so yes.

The second Protocal question caused the most problems. Under the old approach there would not have been infringement because the unpredictability of substituting other salts means that it would not have been obvious at the date of the patent that the Actavis product was an immaterial variant. Neuberger disliked this, as it showed the artificiality of treating this purely as a matter of interpretation.

He preferred a more pragmatic approach, stripped out the time limitation and effectively asked "can you tell from the patent, with knowledge at the date of infringement, whether it's an equivalent (ie. you don't have to guess if it works, and you can consider recent developments in the technology)?". Therefore, in the present case, the question wasn't 'might it have been obvious that other salts are an immaterial variant?', but 'given that the other salts achieve the same result, would it be obvious that they did so in the same way?'. Based on the facts, his answer again was 'yes'.

The third Protocol question of 'strict compliance' is still largely applicable, and could be expressed as 'did the patent nonetheless exclude the equivalent?'. Thankfully, this was considered from the perspective of the whole specification and again at the infringement date. Infringement was found.

Relevance of the file history

We'll look at what this means for patent attorneys below, but the change that has more immediate implications stems from the judge's consideration of the EP file history. The instruction is that we should now consider it, but 'sceptically', and only where it unambiguously resolves a point, or is in the public interest (e.g. where the patentee had expressly excluded an interpretation during prosecution). Having said that, Lord Neuberger used the file history for confirmatory purposes here; the original claims were broad; the permitted amendment to Pemetrexed disodium was occasioned by intermediate generalisation objections, and so strict compliance isn't required.

This has implications both for drafting and prosecution (and although it doesn't affect the decision, practitioners may agree that the evidence given to Lord Neuberger on the operation of the EPO may have been a little sketchy), so patent examiners might be interested to read the relevant passages of the decision too.

What does this mean for a patent attorney?

  1. The test for infringement really is more pragmatic. You can expressly use knowledge of the invention and you can read the patent sensibly and assess whether there is an immaterial variant. In terms of certainty, there was always an argument that consulting the file history was a step too far. But, surely everyone already has a glance at it. Also, the most convincing argument against taking it into account appears to have been Lord Hoffman's statement, 'life is too short'! That was back in 2005, but accessing the file is now a matter of a couple of clicks, at least at the EPO. As long as we are not entering an era of pitched battles about what the content of a file history means, this seems a welcome development.
  2. Judging by the 'light touch' level of knowledge of what goes on at the EPO prosecution level, in this particular case, practitioner knowledge may be absolutely vital in analysing the file. We therefore may see more attorneys appearing as experts in this area.
  3. Less welcome is the impact on our daily practice before Patent Offices. What's done is done, and it's probably best not losing sleep about existing skeletons in closets. There is no suggestion that anything but the immediate file history is considered relevant (but of course someone is going to try and cite patent family members in other jurisdictions).

    Besides, we're usually so aware of the potential impact of statements here in, say, US equivalent proceedings that we're pretty careful anyway. Naturally, we should avoid statements expressly excluding certain interpretations - we have Lord Neuberger's clear guidance on that.

    Note, however, that unlike in many jurisdictions, the use of a limiting amendment did not restrict the scope of the claim. The judge looked at the original broad claim, concluded that strict restriction to a particular Pemetrexed salt was not intended, and then extended the claim scope more broadly than the eventual allowed wording on that basis.

    However, the context and presentation of the amendment here were relevant. As it was required to overcome an intermediate generalisation objection (to the judge's apparent bemusement) there were no limiting statements in the accompanying submissions that might otherwise have caused problems. In essence, when making any amendment or statement to the office in the future, the attorney should imagine the judge reading it and drawing inferences about the patentee's intent.

  4. When it comes to drafting, the importance of dealing with potential added matter issues arises once again. Put in as much basis as you can, and consider a 'pyramid' of terminology from the broadest expression of a feature, through intermediate or alternative formulations, to the narrowest. The reality is that the perfect wording is usually only available in hindsight, as was undoubtedly the case here, and you could take comfort from the fact that in the end the court generously generalised the eventual term. Or you could consider how much cheaper it would have been to have been literally infringed...


This is an important decision, and it is useful to consider its impact not just on litigators, but prosecutors, drafters and even examiners. Current best practice may not have changed too much, but every interaction with the patent office now carries just a little more weight, and the 'how would a judge read this' test needs to become second nature when formulating a response. At the broader level, it feels like a welcome clarification or confirmation of a practical application of the infringement determination tests, despite the extra pressure on patent attorneys. We will wait to see if this more 'pragmatic' approach develops not just in the UK but across Europe, and turns out to be as significant as it looks.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions